Hims & Hers Health, Inc. (HIMS) Tops Q2 EPS by 5c, Revenue Guidance Beats

Hims & Hers Health, Inc. (NYSE: HIMS) reported Q2 EPS of ($0.05), $0.05 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $60.7 million versus the consensus estimate of $56.49 million.

GUIDANCE:

Hims & Hers Health, Inc. sees FY2021 revenue of $251-255 million, versus the consensus of $226.3 million.

• Adjusted EBITDA to be in the range of $(35) million to $(40) million.

Hims & Hers Health, Inc. sees Q3 2021 revenue of $69-71 million, versus the consensus of $58.3 million.

• Adjusted EBITDA to be in the range of $(9) million to $(11) million.

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.

You May Also Be Interested In

• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
• Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals